Cargando…

In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies

BACKGROUND: Since the last COVID-19 outbreak, several approaches have been given a try to quickly tackle this global calamity. One of the well-established strategies is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same paradigm, we report in...

Descripción completa

Detalles Bibliográficos
Autores principales: Matondo, Aristote, Dendera, Washington, Isamura, Bienfait Kabuyaya, Ngbolua, Koto-te-Nyiwa, Mambo, Hilaire V S, Muzomwe, Mayaliwa, Mudogo, Virima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391940/
https://www.ncbi.nlm.nih.gov/pubmed/35996620
http://dx.doi.org/10.2147/AABC.S366111
_version_ 1784770964024721408
author Matondo, Aristote
Dendera, Washington
Isamura, Bienfait Kabuyaya
Ngbolua, Koto-te-Nyiwa
Mambo, Hilaire V S
Muzomwe, Mayaliwa
Mudogo, Virima
author_facet Matondo, Aristote
Dendera, Washington
Isamura, Bienfait Kabuyaya
Ngbolua, Koto-te-Nyiwa
Mambo, Hilaire V S
Muzomwe, Mayaliwa
Mudogo, Virima
author_sort Matondo, Aristote
collection PubMed
description BACKGROUND: Since the last COVID-19 outbreak, several approaches have been given a try to quickly tackle this global calamity. One of the well-established strategies is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same paradigm, we report in the present study, an investigation of the potential inhibitory activity of 5-FU and nineteen of its analogues against the SARS-CoV-2 main protease (3CLpro). MATERIAL AND METHODS: Molecular docking calculations were performed to investigate the binding affinity of the ligands within the active site of 3CLpro. The best binding candidates were further considered for molecular dynamics simulations for 100 ns to gain a time-resolved understanding of the behavior of the guest-host complexes. Furthermore, the profile of druggability of the best binding ligands was assessed based on ADMET predictions. Finally, their chemical reactivity was elucidated using different reactivity descriptors, namely the molecular electrostatic potential (MEP), Fukui functions and frontier molecular orbitals. RESULTS AND DISCUSSION: From the calculations performed, four candidates (compounds 14, 15, 16 and 18) show promising results with respect to the binding affinity to the target protease, 3CLpro, the therapeutic profile of druggability and safety. These compounds are maintained inside the active site of 3CLpro thanks to a variety of noncovalent interactions, especially hydrogen bonds, involving important amino acids such as GLU166, HIS163, GLY143, ASN142, HIS172, CYS145. Molecular dynamics simulations suggest that the four ligands are well trapped within the active site of the protein over a time gap of 100 ns, ligand 18 being the most retained. CONCLUSION: In line with the findings reported herein, we recommend that further in-vitro and in-vivo investigations are carried out to shed light on the possible mechanism of pharmacological action of the proposed ligands.
format Online
Article
Text
id pubmed-9391940
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93919402022-08-21 In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies Matondo, Aristote Dendera, Washington Isamura, Bienfait Kabuyaya Ngbolua, Koto-te-Nyiwa Mambo, Hilaire V S Muzomwe, Mayaliwa Mudogo, Virima Adv Appl Bioinform Chem Original Research BACKGROUND: Since the last COVID-19 outbreak, several approaches have been given a try to quickly tackle this global calamity. One of the well-established strategies is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same paradigm, we report in the present study, an investigation of the potential inhibitory activity of 5-FU and nineteen of its analogues against the SARS-CoV-2 main protease (3CLpro). MATERIAL AND METHODS: Molecular docking calculations were performed to investigate the binding affinity of the ligands within the active site of 3CLpro. The best binding candidates were further considered for molecular dynamics simulations for 100 ns to gain a time-resolved understanding of the behavior of the guest-host complexes. Furthermore, the profile of druggability of the best binding ligands was assessed based on ADMET predictions. Finally, their chemical reactivity was elucidated using different reactivity descriptors, namely the molecular electrostatic potential (MEP), Fukui functions and frontier molecular orbitals. RESULTS AND DISCUSSION: From the calculations performed, four candidates (compounds 14, 15, 16 and 18) show promising results with respect to the binding affinity to the target protease, 3CLpro, the therapeutic profile of druggability and safety. These compounds are maintained inside the active site of 3CLpro thanks to a variety of noncovalent interactions, especially hydrogen bonds, involving important amino acids such as GLU166, HIS163, GLY143, ASN142, HIS172, CYS145. Molecular dynamics simulations suggest that the four ligands are well trapped within the active site of the protein over a time gap of 100 ns, ligand 18 being the most retained. CONCLUSION: In line with the findings reported herein, we recommend that further in-vitro and in-vivo investigations are carried out to shed light on the possible mechanism of pharmacological action of the proposed ligands. Dove 2022-08-15 /pmc/articles/PMC9391940/ /pubmed/35996620 http://dx.doi.org/10.2147/AABC.S366111 Text en © 2022 Matondo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Matondo, Aristote
Dendera, Washington
Isamura, Bienfait Kabuyaya
Ngbolua, Koto-te-Nyiwa
Mambo, Hilaire V S
Muzomwe, Mayaliwa
Mudogo, Virima
In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title_full In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title_fullStr In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title_full_unstemmed In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title_short In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies
title_sort in silico drug repurposing of anticancer drug 5-fu and analogues against sars-cov-2 main protease: molecular docking, molecular dynamics simulation, pharmacokinetics and chemical reactivity studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391940/
https://www.ncbi.nlm.nih.gov/pubmed/35996620
http://dx.doi.org/10.2147/AABC.S366111
work_keys_str_mv AT matondoaristote insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT denderawashington insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT isamurabienfaitkabuyaya insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT ngboluakototenyiwa insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT mambohilairevs insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT muzomwemayaliwa insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies
AT mudogovirima insilicodrugrepurposingofanticancerdrug5fuandanaloguesagainstsarscov2mainproteasemoleculardockingmoleculardynamicssimulationpharmacokineticsandchemicalreactivitystudies